Cefonicid Sodium

CHEMBL1201005 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
586.5 g/mol
LogP
Phase
4

The sodium salt formulation of cefonicid retains the long-acting second-generation cephalosporin activity suitable for once-daily parenteral administration. It is used for respiratory, urinary, skin, and bone infections in outpatient and inpatient settings. Standard cephalosporin precautions regarding allergy history and renal function apply.

आणविक भार

586.5000 g/mol

TPSA

270.00 Ų

क्रिया का तंत्र

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C([O-])C1=C(CSc2nnnn2CS(=O)(=O)[O-])CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12.[Na+].[Na+]

InChI

InChI=1S/C18H18N6O8S3.2Na/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32;;/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32);;/q;2*+1/p-2/t11-,13-,16-;;/m1../s1

Molecular Formula

C18H16N6Na2O8S3

HBD / HBA

2 / 13

घूर्णनीय बंधन

7

भारी परमाणु

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

The sodium salt formulation of cefonicid retains the long-acting second-generation cephalosporin activity suitable for once-daily parenteral administration. It is used for respiratory, urinary, skin, and bone infections in outpatient and inpatient settings. Standard cephalosporin precautions regarding allergy history and renal function apply.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefonicid Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201005. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 43593. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.